Decreased

[키워드] accumulate ACE2 acute respiratory syndrome Against Alpha analyzed Antibody neutralization approaches B.1.1.7 B.1.427 B.1.617.1 B.1.617.2 binding BNT162b2 BNT162b2 mRNA Cohort coronavirus coronavirus 2 COVID-19 COVID-19 mRNA vaccine COVID-19 mRNA vaccines Decreased Delta domain dose E484K/Q mutation Epsilon evade FIVE flow cytometry Gamma healthcare worker Healthcare workers healthcare workers (HCW) heterogeneity highest immune protection knowledge L452R magnitude Moderna mRNA mRNA vaccine mRNA vaccines mRNA1273 Mutation naïve individual naïve individuals natural infection Neutralizing Neutralizing activity Neutralizing antibodies neutralizing antibodies (NAB) neutralizing antibody neutralizing response P.1 Pfizer-BioNTech provided raise RBD RBD of SARS-CoV-2 RBD variant receiving Receptor binding domain receptor binding domain (RBD) Receptor-binding domain regimen respiratory response SARS-CoV-2 SARS-CoV-2 variant SARS-CoV-2 variants Severe acute respiratory syndrome severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 significant increase significantly higher specific neutralizing antibodies Spike protein Spread subject subsequent tested the RBD vaccinated individuals vaccination Vaccine vaccine doses Vaccine-induced immunity variant Viral viral spike protein viral variant Viral variants Wuhan strain
[DOI] 10.3389/fimmu.2022.816389 PMC 바로가기 [Article Type] Article